| Long name: |
SLC12A6/KCC3 Primary Polyclonal Antibody |
| Also known as: |
SLC12A6/KCC3 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
SLC12A6/KCC3 |
| Specificity: |
This is a highly specific antibody against SLC12A6/KCC3 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human SLC12A6/KCC3 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Alterations of KCC2 expression in the inferior colliculus of rat brain may be related to seizure susceptibility, Conversely, In neurons, KCC2 expression is correlated with an inhibitory response to GABA, KCC2 expression is limited to neuronal tissues by a restrictive element similar to the neuronal-restrictive silencing factor, KCC3 is not suspected to play a major role in epilepsy, KCC3a and KCC3b, Nitric oxide (NO) donors activate KCCs, The two splice variants of KCC3, The ubiquitously expressed KCC1 contains 12 transmembrane domains with both cytoplasmic N and C terminal domains, are predominantly expressed in brain and kidney, brain, heart and kidney, lung, respectively, while KCC4 is expressed in muscle, while inhibitors of the cGMP pathway prevent NO donor activation, while the absence of KCC2 is necessary for an unusual excitatory response to GABA, The four isoforms of potassium/chloride co-transport channels (KCC) belong to a superfamily of cation-chloride co-transporters involved in cell volume maintenance |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
Furosemide sensitive KCl cotransporter 3, Gaxp, KCC 3, KCC 3A, KCC 3B, KCC3, KCC3 A, KCC3 B, KCC3A, KCC3B, Potassium chloride cotransporter 3, Potassium chloride cotransporter KCC3a S3, S12A6_HUMAN, SLC12 A6, SLC12A 6, Solute carrier family 12, Solute carrier family 12 potassium/chloride transporters, member 6, member 6, ACCPN |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
SLC12A6/KCC3 |
| Short name: |
SLC12A6/KCC3 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
SLC12A6/KCC3 (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
10914 |
| Gene: |
SLC12A6 |
More about : SLC12A6 |
| Long gene name: |
solute carrier family 12 member 6 |
| Synonyms gene: |
KCC3 ACCPN |
| Synonyms gene name: |
agenesis of corpus callosum and peripheral neuropathy (Andermann syndrome) solute carrier family 12 (potassium/chloride transporter), member 6 |
| Locus: |
15q14 |
| Discovery year: |
1999-05-25 |
| GenBank acession: |
AF108831 |
| Entrez gene record: |
9990 |
| Pubmed identfication: |
10187864 10347194 |
| RefSeq identity: |
NM_005135 |
| Classification: |
Solute carriers |
| Havana BLAST/BLAT: |
OTTHUMG00000129441 |
| Locus Specific Databases: |
Inherited Peripheral Neuropathies Mutation Database LRG_270 |